Evotec has been boosted by the news that it has expanded its R&D pact with fellow German drugmaker Boehringer Ingelheim.

The Hamburg-headquartered firm noted that it has extended the research collaboration with Boehringer for a further four years. The link-up was initiated in August 2004 and has been extended on two previous occasions.

Evotec added that, based on the success to date in the areas of central nervous system, inflammation, cardiometabolic and respiratory diseases, the scope of the collaboration has been expanded to also include oncology targets. Over the term of the extension, it will receive research funding of around 15 million euros, plus success milestones and royalties.

Evotec chief executive Werner Lanthaler said his firm is “extremely pleased and proud” that Boehringer “continues to see the value that we bring to their research, by committing to one of the largest and most innovative integrated research projects in the industry”. Boehringer certainly seems happy and Wolfgang Rettig, senior vice president of research, noted that “Evotec has continually demonstrated exceptional scientific expertise in support of our research”.

Last month, Evotec achieved its seventh milestone in its collaboration with Boehringer, which led to a 2.5 million euro payment. The milestone was achieved for the selection of a candidate compound for pre-development studies in a cardiometabolic programme.